NCT06449846View on ClinicalTrials.gov

Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma

Not yet recruitingOBSERVATIONAL

Enrollment

152

Participants

Timeline

Start Date

June 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Hepatocellular Carcinoma ResectableSurgeryRecurrence

Interventions

DIAGNOSTIC_TEST

circulating tumor cell DNA detection

circulating tumor DNA blood sample and tissue specimen for circulating tumor DNA will be done to patient with hepatocellular carcinoma

Trial Locations (4)

510220

Zhujiang Hospital of Southern Medical University, Guangzhou

Unknown

Shunde Hospital of Southern Medical University, Foshan

The Sixth Affiliated Hospital of South China University of Technology, Foshan

Sun Yat-sen University Cancer Center, Guanzhou

All Listed Sponsors

lead

Zhujiang Hospital

OTHER

NCT06449846 - Compare the Accuracy of ctDNA-MRD and MVI Result in Predicting Postoperative Recurrence of Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter